TEDOR Pharma, Inc., a full-service contract development and manufacturing organization (CDMO), has entered an agreement to provide cGMP contract manufacturing services for the Center for International Health Research at Rhode Island Hospital.

TEDOR will support a clinical trial exploring the safety and efficacy of Praziquantel in children under the age of four. TEDOR is expected to serve as Rhode Island Hospital’s qualified manufacturing partner for any further development requirements.

Jennifer Friedman, MD, PhD said, “We are pleased to be working with TEDOR on this important project. Their location, capabilities, and facilities are a very good match for our program.”

“We are delighted to partner with Rhode Island Hospital to provide Phase II clinical trial manufacturing services,” said Doug Drysdale, President and CEO of TEDOR Pharma.  “Our extensive experience in manufacturing combination products makes TEDOR well suited to provide both clinical trial supply and eventual commercialization.”